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Objectives: Heart failure is one of the leading causes of death in the U.S. The incorporation of B-type 
natriuretic peptide (BNP) measurements when triaging patients presenting with shortness of breath 
has improved the diagnostic and prognostic ability of physicians. Currently, there are no point-of-care 
systems for quantifying BNP that can be used without sacrificing accuracy. We compared the analytical 
performance of the Abbott i-STAT analyzer, a handheld point-of-care system for measuring BNP, with the 
lab-based system, the Abbott ARCHITECT. 
Methods: One-hundred fifty samples were collected from three clinical settings: 41 from the Emergency 
Department, 58 from the inpatient wards, and 51 from heart failure outpatient clinics. Linear regression and 
bias difference analyses were run to evaluate the accuracy of the i-STAT. Correlation between the i-STAT 
and Architect BNP values were made with values of BNP. 
Results: The correlation coefficient was r=0.977 (N=150, p<.0001). The average bias was significant (-36) 
and there were concentration-dependent differences at higher BNP values. Precision of the i-STAT was 
poor compared to the lab-based platform. 
Conclusion: Although the precision of the i-STAT was poor, there was good clinical agreement between 
the i-STAT and the lab-based platform. [West J Emerg Med. 2010; 11(1):44-48].
INTRODUCTION
Heart failure (HF) is one of the leading causes of death 
in the U.S. About five million Americans have this disease, 
and approximately 550,000 new cases are identified each 
year.1 The estimated direct and indirect cost of HF in the U.S. 
for 2006 was $29.6 billion.1 With improving diagnosis and 
management of acute myocardial infarction and HF, it is likely 
this cost will continue to increase over time. The number of 
HF-related hospital admissions has been steadily rising in 
developed countries. The economic burdens of HF are caused 
by the high number of hospital admissions for initial treatment 
and high costs of long term care for these patients.2 While 
the most common disease group in patients over 65 is HF,2 
it remains difficult to diagnose due to a lack of sensitive and 
specific presenting symptoms.3 Furthermore, a misdiagnosis 
in the emergency department (ED) could place a dyspneic 
patient at increased risk for both morbidity and mortality.4 The 
“gold standard” for diagnosis is echocardiography, which is 
not generally available in the emergency setting. Due to the 
alarming costs of HF, there is an urgent need to detect patients 
at risk of developing HF and establishing timely therapy to 
prevent irreversible changes that can lead to chronic HF.
Incorporation of B-type natriuretic peptide (BNP) 
measurements when triaging patients presenting with 
shortness of breath has improved the diagnostic and 
prognostic ability of treating physicians. In the “Breathing 
Not Properly Multinational Study,” in 1,586 ED patients 
presenting with acute shortness of breath, BNP levels 
measured on arrival had higher diagnostic accuracy than did 
the ED physician in diagnosing HF, with an area under the 
receiver-operating characteristic curve (AUC) of 0.90.5 A BNP 
cut-point of 100 pg/mL was 90% sensitive and 76% specific Volume XI, no. 1  :  February 2010             45  Western Journal of Emergency Medicine
for diagnosing HF as the cause of dyspnea. 
Current turnaround times for BNP values, including time 
to draw sample, transport to central lab, analyze and report 
values, using lab-based automated analyzers on ED patients is 
typically around one hour.
Shortening this turnaround time in the emergent setting 
could potentially help physicians make a more rapid “rule-in” 
or “rule-out” diagnosis of HF. Mueller et al.6 and Troughton et 
al.7 demonstrated that rapid evaluation of BNP in HF patients 
shortened the time to treatment initiation, decreased the time 
to discharge, decreased the total medical costs for that patient, 
reduced total cardiovascular events, and delayed time to first 
event.
Attempts at providing a more rapid, point-of-care 
(POC) BNP test have suffered from analytical, regulatory, 
and management issues. Our objective in this study was to 
compare the analytical performance of the POC i-STAT® 
system for measuring BNP levels with a standard, lab-
based ARCHITECT® instrument (Abbott Laboratories, 
Abbott Park, IL).
METHODS
Patients for this study were enrolled from the ED, 
inpatient setting, and heart failure clinics at the San Diego 
Veterans Affairs Healthcare System between January 2007 
and January 2008. There were 114 patients, with 41 samples 
collected from the ED setting, 58 samples from the inpatient 
setting, and 51 samples from the clinic/outpatient setting. 
Thirty-six patients from the ED were later admitted and were 
sampled again as inpatients. Distribution of patients included 
110 males (mean age 68, range 38-90 yrs) and four females 
(mean age 59, range 46-83 yrs.). Inclusion criteria were 
presentation with heart failure (HF) symptoms in the ED, 
hospitalization for HF, or visitation in a heart failure clinic. 
Patients on dialysis, patients with trauma-related shortness 
of breath and patients unwilling to sign a consent form were 
not enrolled in the study. The study was approved by review 
through the Institutional Review Board at the University of 
California, San Diego. 
The i-STAT BNP test is a handheld in vitro diagnostic 
test for the quantitative measurement of BNP. The i-STAT 
BNP cartridge uses a two-step sandwich immunoassay using 
monoclonal antibodies specific for BNP. The i-STAT BNP 
test uses the same antibodies as the ARCHITECT BNP assay. 
The capture antibody recognizes amino acids 5 to 13 and the 
detection antibody that recognizes amino acids 26 to 32 of the 
BNP molecule.10 The i-STAT analyzer and BNP cartridges and 
controls were provided by Abbott, as was the ARCHITECT. 
Statistical analysis was conducted using SigmaPlot (Systat, 
San Jose, CA). 
Lavender-top, ethylenediaminetetraacetic acid (EDTA) 
whole blood specimens were obtained in plastic tubes; plasma 
was isolated and stored at -80 degrees Celsius until analysis. 
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Table 1. Demographics and lab values
Number 
(n=114)
Percent
Age 63.7 + 11.8
Sex
Male 110 96 %
Female 4 4 %
Race
Caucasian 75 67 %
African American 19 17 %
American Indian / Alaskan Native 4 4 %
Asian / Pacific Islander 3 3 %
Hispanic 9 8 %
Other/Unknown 4 4 %
Past Medical History
CHF 96 84 %
CAD 64 56 %
HTN 86 75 %
CHF Etiology
Alcohol 8 7 %
Cocaine 3 3 %
Hypertensive 6 5 %
Hypertropic 2 2 %
Idiopathic 6 5 %
Ischemic 47 41 %
Myocarditis 1 1 %
Valvular 6 5 %
Other/Unknown 17 15 %
Admission Labs Average Range
BNP pg/mL 319 12-4560
Sodium mEq/L 139 127-145
Glucose mg/dL 107 60-390
BUN mg/dL 22.5 5-125
Creatinine mg/dL 1.3 0.7-20
WBC x 103/μL 7.3 2.3-56
Hemoglobin g/dL 12.9 8-124
Platelets x 103/μL 206 12-559
CHF, congestive heart failure; CAD, coronary artery disease; HTN, 
hypertension; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; 
WBC, white blood count.
Samples were thawed and analyzed weekly in batches on the 
ARCHITECT and i-STAT. The ARCHITECT and i-STAT 
measurements were performed at the same time. All personnel 
running the devices were laboratory staff, trained on the operation 
of both devices. Linearity and precision of each device or assay 
was performed using materials provided by the manufacturer.Western Journal of Emergency Medicine            46  Volume XI, no. 1  :  February 2010
Linear regression analyses were done and bias 
differences were analyzed according to Bland and Altman.11 
Within-run and run-to-run precision data was obtained on 
the i-STAT analyzer at both a high and low level. High and 
low controls were run on the i-STAT analyzer 15 times in 
one day for within-run calculations. High- and low-level 
precision controls were run on the i-STAT analyzer twice 
a day for 15 days for run-to-run calculations. High- and 
low-level precision controls were run on the ARCHITECT 
15 times in one day for within-run calculations. High- and 
low-level precision controls were run on the ARCHITECT 
in duplicate twice a day for five days for run-to-run 
calculations. An F test was used to compare the variance 
of the i-STAT and the ARCHITECT. A p-value < 0.05 was 
considered significant.
RESULTS
Sample population characteristics and median lab 
values are shown in Table 1. Results of precision testing 
comparing the i-STAT and ARCHITECT are shown in 
Table 2. For the i-STAT, run-to-run precision (%CV) for 
the low level (mean=122 pg/mL) was 14% and for the high 
level (mean=3274 pg/mL) 9.8%. Within-run precision on 
the i-STAT analyzer for the low level was 17% and for the 
high level 19%. For the ARCHITECT instrument, run-to-
run precision (%CV) for the low level (mean=99 pg/mL) 
was 5.5% and for the high level (mean=3428 pg/mL) 3.2%. 
Within-run precision using the ARCHITECT instrument for 
the low level was 1.8% and 5.7% for the high level.
To determine the accuracy of the BNP i-STAT 
analyzer, we compared results with those obtained on 
the ARCHITECT. The range of BNP values obtained on 
patients for the i-STAT and ARCHITECT was 5 – 5000 
pg/mL. Correlations between plasma measurements made 
with i-STAT and those made with ARCHITECT are shown 
in Figure 1. Linear regression between the i-STAT and the 
reference system showed r=0.977 (p<.0001). 
In Figure 2, a difference bias plot for the total sample 
population was constructed according to Bland and 
Altman.9 The average bias was -36.01 with significant 
concentration-dependent differences at higher BNP values. 
DISCUSSION
In this study we evaluated the performance of a 
handheld POC BNP analyzer against a standard lab-
based model. In terms of correlation with the laboratory 
analyzer, the i-STAT analyzer performed remarkably 
well with a cumulative correlation of 0.977 for the entire 
cohort. However, the precision of the i-STAT was poor as 
compared with the ARCHITECT system. 
POC testing for BNP, similar to use of troponins in 
ACS, is a logical progression in the treatment and risk 
stratification of patients with HF; however, the i-STAT, 
with its unique strengths (decreased therapeutic turnaround 
time, rapid data availability, accuracy) and weaknesses 
(precision, handling error, cost), proves to be most useful 
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Table 2. Within-run and Run-to-run Precision of i-STAT and 
ARCHITECT
Within-run Run-to-run
N Mean
pg/mL
CV
%
N Mean
pg/mL
CV
%
i-STAT 15 122 17 30 122 14
15 3275 19 30 3275 9.8
ARCHITECT 15 99 1.8 20 99 5.5
15 3428 5.7 20 3428 3.2
CV%, run-to-run precision.
Figure 1: B-type natriuretic peptide (BNP) values as determined 
with the i-STAT vs ARCHITECT for the entire patient cohort.
Figure 2: Bland-Altman plot of B-type natriuretic peptide (BNP) 
values as determined with the i-STAT vs ARCHITECTVolume XI, no. 1  :  February 2010             47  Western Journal of Emergency Medicine
in the emergent setting as a bridge to the inpatient stay 
and subsequent lab-based analyses. The main weakness 
of the i-STAT BNP, like other POC systems, is its lack 
of precision. From the emergency physician’s (EP) 
perspective, knowledge of the BNP upon presentation is 
important in guiding treatment plan. The positive predictive 
value of BNP at 100 pg/mL is 75% and 86% at 400 pg/
mL.5 In addition, a presenting BNP value of below 200 pg/
mL is an excellent predictor of 90-day prognosis.8 While 
a BNP value of over 480 pg/mL was a strong predictor of 
6-month CHF death, hospital readmission, or repeat ED 
visits.9 Therefore, knowledge of a specific BNP value (not 
just a “rule-in” vs. “rule-out” value) is useful to the EP 
in directing treatment of a patient presenting with CHF 
exacerbation. The average bias of -36.01 pg/mL and the 
relatively poor precision of the i-STAT analyzer has to 
be taken into account when considering implementation 
of the device, because the difference in precision does 
make a clinical difference in managing a patient with CHF 
exacerbation.
The strength of the i-STAT BNP complements the 
current evolution of the treatment and management of HF 
as a disease. Once thought to be simply a hemodynamic 
instability where a patient was either “in” HF or “out of” 
HF, there is now a greater appreciation for the progressive 
nature of the disease. Recognizing that remodeling of 
the heart is constant and gradated means treatment no 
longer focuses solely on the hemodynamics (diuretics 
and digitalis) but also includes attention to the heart as 
a dynamic neuroendocrine organ (ACE inhibitors).12 
The need for a rapid POC system to evaluate BNP in 
HF patients is two-fold: rapidity and integration into HF 
management.
While the ARCHITECT instrument takes less than 16 
minutes to analyze BNP values, turnaround times of results 
generally less than one hour due to specimen-processing 
and transportation issues. The i-STAT analyzer takes only 
10 minutes and can be readily available in the ED. Early 
assessment of the degree of hemodynamic compromise 
(measured indirectly with BNP) allows physicians to 
make the appropriate medical interventions necessary to 
minimize damage to the heart. A rapidly obtained BNP 
value could prove useful in the ED setting or in the clinic 
setting, for ruling in/out HF. Furthermore, previous studies 
have shown that shortened times to BNP evaluation in the 
emergent setting resulted in quicker treatment initiation and 
shorter hospital stays.3
Cost analysis is another factor to be considered when 
contrasting the i-STAT analyzer with the ARCHITECT 
instrument. Studies have shown that the cost of using POC 
testing over central laboratory can increase costs 1.1 to 
4.6 times.13 The ability to gain a rapid BNP value in the 
emergent setting would most likely come at a higher cost 
than continuous use of a central laboratory. However, the 
i-STAT analyzer, providing a more rapid result, would lead 
to shorter hospital stays which would reduce costs for the 
institution.3 Fiscal considerations should be urged before 
erroneously implementing this platform into a hospital 
setting.
 
LIMITATIONS
The study population was drawn from the Veterans 
Affairs Medical Center and was 96% male. Thus, these 
results need to be confirmed in a non-Veterans Affairs 
population and with women. In addition, the analyses were 
not performed in real time. Samples were frozen and batch-
run, so the study can be considered “in-vitro.” However, 
the strength of the i-STAT remains valuable to the EP in the 
event of an emergent presentation.
CONCLUSION
Previous POC systems correlate poorly with the lab-
based instruments, making it difficult for the physician 
to interpret and track changes in the BNP levels from ED 
presentation throughout the hospital stay.14 In contrast, 
the i-STAT BNP test utilizes the same antibody as the 
ARCHITECT BNP assay and, consequently, demonstrates 
reasonable agreement between the two methods. This 
provides essential continuity in tracking BNP changes 
throughout the hospital stay and could allow for accurate 
charting of a patient’s response to therapy. The emerging 
technology of a rapid POC BNP assay allows physicians to 
rapidly triage patients and may allow physicians to initiate 
treatment more rapidly. This could potentially reduce 
medical costs and total cardiovascular events. Although the 
i-STAT lacks precision, it could serve as a practical tool in 
the clinic setting and emergent setting for acquiring a rapid 
initial BNP value for managing patients.
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